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Objectives This study sought to assess the effects of rolofylline on renal function in patients with acute heart failure (AHF)
and renal dysfunction randomized in PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adeno-
sine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Vol-
ume Overload to Assess Treatment Effect on Congestion and Renal Function).
Background Small studies have indicated that adenosine A1 receptor antagonists enhance diuresis and may improve renal
function in patients with chronic heart failure or AHF.
Methods A total of 2,033 patients with AHF, volume overload, estimated creatinine clearance between 20 and 80 ml/min,
and elevated natriuretic peptide levels were randomized (2:1) within 24 h of hospital presentation to rolofylline
30 mg/day or intravenous placebo for up to 3 days. Creatinine was measured daily until discharge or day 7 and
on day 14. Persistent worsening renal function was defined as an increase in serum creatinine 0.3 mg/dl at
both days 7 and 14, or initiation of hemofiltration or dialysis or death by day 7.
Results At baseline, mean  SD estimated creatinine clearance was 51.0  20.5 ml/min in the placebo group and
50.4  20.0 ml/min in the rolofylline group. Changes in creatinine and estimated creatinine clearance were
similar between placebo- and rolofylline-treated patients during hospitalization and at day 14. After 4 days,
mean body weight was reduced by 2.6 and 3.0 kg in placebo and rolofylline patients, respectively (p  0.005).
Persistent worsening renal function occurred in 13.7% of the placebo group and 15.0% of the rolofylline group
(odds ratio vs. placebo: 1.11 [95% confidence interval: 0.85 to 1.46]; p  0.44).
Conclusions In this large, phase III clinical trial, the adenosine A1 receptor antagonist rolofylline did not prevent persistent
worsening renal function in AHF patients with volume overload and renal dysfunction. (A Study of the Selective
A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to
Assess Treatment Effect on Congestion and Renal Function [PROTECT-1], NCT00328692; and [PROTECT-2],
NCT00354458) (J Am Coll Cardiol 2011;57:1899–907) © 2011 by the American College of Cardiology Foundation
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Renal Effects of Rolofylline in Acute HF May 10, 2011:1899–907Renal dysfunction is common in
patients who are admitted for
acute heart failure (AHF) and is
associated with increased mortal-
ity and rehospitalization during
follow-up (1). In addition, wors-
ening renal function (WRF), of-
ten defined as an increase in se-
rum creatinine of 0.3 mg/dl
during hospitalization, occurs in
approximately 30% of patients
and is independently related to
an even poorer prognosis (2–6).
Impaired renal function at ad-
mission, and deterioration of re-
nal function during hospitaliza-
tion, may simply reflect sicker patients with more severe
heart failure (HF) and, therefore, may be related to worse
outcomes. However, renal dysfunction itself may contribute
to deterioration of HF (7). Multiple mechanisms may
be involved in renal dysfunction, including increased sodium
and fluid retention, neurohormonal activation (8), and
resistance to loop diuretics (9). However, a causal relation
between renal dysfunction and adverse outcomes in HF can
only be established with therapies that improve renal func-
tion and clinical outcomes in AHF, without exerting sys-
temic hemodynamic or cardiotoxic or renal toxic effects.
Adenosine is increased in HF patients, because of im-
paired renal perfusion, venous congestion, and hypoxia
(10–13). In addition, adenosine production is stimulated by
the use of diuretics. Through stimulation of the adenosine
A1 receptor on the glomerular afferent arteriole, adenosine
educes renal blood flow and glomerular filtration rate
GFR), and through stimulation of the adenosine A1
receptor on the proximal tubules, it increases sodium and
water reabsorption (12). The adenosine A1 receptor antag-
onist rolofylline enhanced diuresis in patients with AHF
and significantly increased GFR and renal plasma flow in
ambulatory patients with chronic HF (14,15). In a dose-
ranging study of 301 patients with AHF and an estimated
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2010, accepted November 18, 2010.creatinine clearance (eCrCl) between 20 and 80 ml/min (the
PROTECT Pilot [Effects of Rolofylline, a New Adenosine
A1 Receptor Antagonist on Symptoms, Renal Function,
and Outcomes in Patients With Acute Heart Failure] trial),
rolofylline 30 mg/day was associated with a more than 50%
reduction in the risk of persistent WRF (16). In the present
study, we describe the effects of rolofylline on renal function in
2,033 AHF patients that were included in PROTECT
(Placebo-Controlled Randomized Study of the Selective A1
Adenosine Receptor Antagonist Rolofylline for Patients Hos-
pitalized With Acute Decompensated Heart Failure and Vol-
ume Overload to Assess Treatment Effect on Congestion and
Renal Function) (17), a large, phase III randomized clinical
trial. Our intent was to supplement the results of the primary
publication by providing additional details about the renal
effects of this therapy.
Methods
Patients. We enrolled 2,033 patients who were 18 years
of age, hospitalized for AHF with dyspnea at rest or with
minimal exertion and signs of fluid overload (manifest by
jugular venous pressure 8 cm, pulmonary rales  one-
hird up the lung fields, or 2 peripheral or presacral
dema), and had an anticipated need for intravenous furo-
emide40 mg/day (or equivalent) for at least 24 h after the
tart of study drug. Other inclusion criteria were the
resence of impaired renal function (eCrCl between 20
nd 80 ml/min by the Cockcroft-Gault equation [cor-
ected for height in edematous or obese subjects 100
g]); elevated natriuretic peptide levels (B-type natri-
retic peptide or N-terminal pro–B-type natriuretic pep-
ide 500 or 2,000 pg/ml, respectively); and eligibility
or randomization within 24 h of presentation. Key
xclusion criteria have been described elsewhere and
nclude a systolic blood pressure 90 or 160 mm Hg,
acute coronary syndrome, and ongoing or planned treat-
ment with ultrafiltration or dialysis (18).
Study procedures. The trial was approved by the ethics
committees at each participating center, and patients
provided written informed consent. Intravenous rolofyl-
line 30 mg or placebo was administered as a 4-h infusion
daily for 3 days in a double-blind manner according to a
computer-generated randomization scheme (allocated 2:1
active to placebo). Patient follow-up continued until the
last enrolled patient reached the 180-day point. Tele-
phone contact was made at 60 days to assess vital status
and identify hospital readmissions and at 180 days to
assess vital status.
Laboratory measurements. At baseline (day 1), days 2 to 6
or discharge if earlier, and days 7 and 14, blood samples
were obtained for assessment of serum blood urea nitrogen
(BUN) and creatinine, with measurements performed in a
central laboratory (ICON Laboratories, Farmingdale, New
York). Creatinine was measured using a substrate-triggered
rate-blanked method. When pH is alkaline, creatinine
1901JACC Vol. 57, No. 19, 2011 Voors et al.
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The rate of color formation is proportional to the concen-
tration of creatinine present and can be measured photo-
metrically. This type of measurement minimizes interfer-
ence, and a correction is applied for proteins that
nonspecifically react. When performed on human serum,
the test has a within-run coefficient of variance of 0.7% and
between-run coefficient of variance of 2.3%.
Study outcomes and definitions. The primary endpoint
for this study was a 3-category, ordered outcome of treat-
ment success, no change, or treatment failure. Success was
defined as patient-reported moderate or marked improve-
ment in dyspnea using a 7-point Likert scale at both 24 and
48 h after study drug administration in the absence of any
criterion for failure. Failure criteria included: death or
readmission for HF any time through day 7; or worsening
symptoms and/or signs of HF occurring 24 h after the
start of study drug to day 7 or discharge; or persistent renal
impairment as defined by a serum creatinine increase of
0.3 mg/dl from randomization to day 7, confirmed at day
14, or the initiation of hemofiltration or dialysis or death
through day 7. Unchanged was defined as not meeting the
criteria for either success or failure.
Two secondary outcomes were pre-specified: 1) time to
death from any cause or rehospitalization for cardiovascular
or renal causes through day 60; and 2) the proportion of
subjects with persistent WRF. In addition, the time to
death up to 180 days was assessed (not reported here).
Anemia was defined as a hemoglobin 13 g/dl in men and
12 g/dl in women.
Rules for defining persistent WRF. For the analyses of
the primary and key secondary endpoints, the following data
handling rules were implemented to classify subjects with
respect to persistent WRF for those with incomplete serum
creatinine data:
• Subjects who died or initiated hemofiltration or dial-
ysis by day 7 were classified as having persistent WRF.
• Subjects who died or initiated hemofiltration or dial-
ysis between days 8 and 14 were considered to have a
0.3 mg/dl increase in creatinine at day 14. Therefore,
if the day 7 value was increased0.3 mg/dl the subject
was considered to have persistent WRF.
• The last available creatinine value between days 2 and 6
was substituted for a missing day 7 creatinine value, and
the classification of persistent WRF was based on the
change from day 1 to this value and the day 14 value.
• Subjects with an increase in creatinine 0.3 mg/dl for
the last observation in the time frame up to and
including day 7 but with a missing day 14 creatinine
value were classified as either unchanged or failure
depending on the day that the last available creatinine
value was obtained. If the value was obtained before
day 6, the subject was classified as unchanged. If
the value was obtained on days 6 or 7, the subject was
classified as failure.• Other subjects who did not meet any of the other
failure criteria and who were missing creatinine values
such that a classification of persistent WRF could not
be made were classified as unchanged for the primary
endpoint and missing for the key secondary endpoint.
For the analysis of change from baseline in creatinine, the
last observation carried forward approach was used. For
subjects who died or initiated hemofiltration or dialysis, the
last observation before death or initiation of hemofiltration
or dialysis was used in the analysis.
Statistical methods. The treatment groups were compared
on changes from baseline in serum creatinine, BUN, and
weight using analysis of covariance models with treatment,
study, region, and the respective baseline values as explan-
atory variables. The proportion of patients with persistent
WRF was analyzed using a Cochran-Mantel-Haenszel test
stratified by study and region. Subgroup analyses by baseline
eCrCl category (30 ml/min, 30 to 60 ml/min, 60 to 80
ml/min, and 80 ml/min) of the primary trichotomous
endpoint and the secondary endpoint of time to death from
any cause or rehospitalization for cardiovascular or renal
causes through day 60 were performed using: 1) an ordered
logistic regression model with treatment, baseline eCrCl
category, the interaction of treatment and baseline eCrCl
category, study, and region as explanatory variables; and 2) a
Cox model with treatment, baseline eCrCl category, the
interaction of treatment, and baseline eCrCl category as
explanatory variables and study-by-region as strata,
respectively.
Univariable and multivariable analyses to predict per-
sistent WRF were performed using logistic regression
models. For the multivariable modeling, all explanatory
variables were entered into the model at the same time.
Statistical significance was set at the unadjusted p value
level of 0.05 for the univariable and multivariable models,
with no adjustment for multiplicity. Persistent WRF as
defined for the secondary endpoint was used in the
modeling.
Results
Patients. Of the 2,033 patients, 1,356 were randomized to
rolofylline 30 mg and 677 were randomized to placebo.
Mean age of the patients was 70 years, 33% were women,
and 95% were Caucasian. Most patients (70%) had ischemic
heart disease and comorbid conditions, including hyperten-
sion (79%), atrial fibrillation (55%), and diabetes (45%),
were common. Other baseline characteristics of the study
group are presented in Table 1. There were no significant
differences in baseline characteristics between placebo and
rolofylline-treated patients. In addition, in-hospital treat-
ment in both groups was similar. The median and inter-
quartile range of intravenous (IV) furosemide doses admin-
istered from randomization through day 7 or discharge if
earlier were 280 mg (120 to 545 mg) and 280 mg (140 to
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Renal Effects of Rolofylline in Acute HF May 10, 2011:1899–907620 mg) in the rolofylline and placebo groups, respectively
(p  0.072). Angiotensin-converting enzyme inhibitor or
ngiotensin receptor blocker use increased from 70.0% at
aseline to 81.5% at day 7 or discharge if earlier in the
lacebo group and from 70.0% to 82.6%, respectively, in the
olofylline group. The use of aldosterone blockers also
ncreased similarly in both groups during the hospitalization
rom approximately 46% to 60%.
hange in creatinine, BUN, and weight. At baseline,
erum creatinine was 1.50  0.59 mg/dl in the placebo
roup and 1.52 0.56 mg/dl in the rolofylline group. Overall,
here was a slight and gradual increase in serum creatinine
uring the first few days of hospitalization (Fig. 1A), but there
ere no statistically significant differences in the change from
aseline in serum creatinine between the placebo and rolofyl-
ine groups. There were no statistically significant differences in
he change from baseline in serum creatinine between the
lacebo and rolofylline group at any time during the observa-
ion period.
At baseline, mean BUN was 33.7  17.5 mg/dl in the
Baseline Characteristics and TherapiesTable 1 Baseline Characteristics and Therapies
Placebo
(n  677)
Rolofylline
(n  1,356) p Value*
Demographics
Age, yrs 70 12 70 12 0.94
Male 66.8 67.3 0.82
Caucasian 95.5 95.2 0.73
Measurements
Body mass index 28.8 6.2 28.9 6.1 0.65
Systolic BP, mm Hg 124 18 124 18 0.85
Diastolic BP, mm Hg 74 12 74 12 0.47
Heart rate, beats/min 81 16 80 15 0.22
eCrCl, ml/min 51.0 20.5 50.4 20.0 0.55
LVEF within 6 months, % 33 14 32 13 0.76
Medical history
Ischemic heart disease 68.5 70.5 0.36
Hypertension 77.8 80.2 0.21
Atrial fibrillation 57.0 53.5 0.14
Diabetes 45.8 45.2 0.79
COPD or asthma 19.4 20.0 0.75
Medical therapy
ACE inhibitor or ARB 74.4 76.3 0.36
Beta-blocker 75.7 76.5 0.71
Aldosterone blocker 42.4 44.5 0.36
Nitrates (oral or topical) 23.9 27.0 0.13
Digoxin 29.6 27.3 0.27
Intravenous loop diuretics†
Furosemide 94.1 93.7 0.91
Bumetanide 4.0 4.1 0.97
Ethacrynic acid 0.1 0.1 0.61
Torsemide 1.0 0.9 0.74
Values are mean SD or %. *The p values for comparison of means are from 2-sample t test, and
percentages are from chi-square test. †Received through day 7 or discharge if earlier.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BP  blood
pressure; COPD chronic obstructive pulmonary disease; eCrCl estimated creatinine clearance;
LVEF  left ventricular ejection fraction.lacebo group and 34.3  17.6 mg/dl in the rolofyllinegroup. As seen with serum creatinine, there was a slight and
gradual increase in serum BUN over the first week of
hospitalization (Fig. 1B); with the exception of the change
from baseline at day 2 (p  0.001), there were no statisti-
cally significant differences in the change from baseline in
BUN between the placebo and rolofylline groups.
Patient weight was recorded during the first 4 days of
hospital admission, during which time, there was slightly
greater weight loss in the rolofylline-treated patients. Mean
body weight decreased from 81.8  19.8 kg at baseline to
79.3  19.0 kg at day 4 (p  0.001) in the placebo group,
nd from 82.0  19.4 kg at baseline to 78.7  18.4 kg at
ay 4 (p  0.001) in the rolofylline group (between-
reatment difference: –0.43 [95% confidence interval (CI):
0.73 to –0.13], p  0.005).
ersistent WRF. Persistent WRF, defined as an increase in
erum creatinine of 0.3 mg/dl from randomization to day
, confirmed at day 14, or the initiation of hemofiltration or
ialysis or death through day 7, occurred in 13.7% of the
lacebo group and 15.0% of the rolofylline group (odds ratio
Figure 1 Changes in Renal Function
Mean change in serum creatinine (A) and blood urea nitrogen (BUN) (B) in
patients randomized to placebo (triangles) or rolofylline 30 mg (circles).
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Table 2). Compared with patients with stable or improved
enal function, patients who developed persistent WRF
ere older; more likely to have ischemic heart disease,
nemia, and chronic lung disease; and less likely to be
reated with neurohormonal antagonists and digoxin
Table 3). Patients with persistent WRF also had a lower
CrCl at baseline (46 ml/min vs. 51 ml/min) and a higher
jection fraction measured within 6 months. A multivari-
ble analysis was performed to establish predictors of
ersistent WRF (Table 4). In this analysis, the presence
f anemia was the only significant predictor of persistent
RF (OR: 1.61 [95% CI: 1.21 to 2.14]; p  0.001),
hereas older age (OR: 1.14 [95% CI: 0.99 to 1.31] per
0 years; p  0.070), lower baseline eCrCl (OR: 0.92
95% CI: 0.58 to 1.01] per 10 ml/min; p  0.061), and
iabetes (OR: 0.77 [95% CI: 0.58 to 1.01]; p  0.058)
remained of borderline significance.
Effects of rolofylline on endpoints in relation to baseline
renal function. Pre-specified subgroup analyses were per-
formed on the primary and secondary endpoints in patients
according to baseline eCrCl: 30 ml/min (n  281), 30 to
60 ml/min (n  1,094), 60 to 80 ml/min (n  412), and
80 ml/min (n  156). The primary trichotomous end-
oint of treatment success, unchanged, or failure was similar
etween rolofylline- and placebo-treated patients across
hese subgroups, although the OR for rolofylline (1.0
ndicating better outcome and 1.0 indicating poorer out-
ome) was 0.88 (95% CI: 0.56 to 1.26) in patients with
CrCl 30 ml/min and 1.37 (95% CI: 0.72 to 2.81) in
atients with eCrCl 80 ml/min (Fig. 2). The secondary
orbidity/mortality endpoint, the risk of death or cardio-
ascular or renal rehospitalization through day 60, was lower
n the rolofylline group compared with the placebo group
nly in patients with a baseline eCrCl 30 ml/min (hazard
atio: 0.64; 95% CI: 0.43 to 0.95), but not in the other
ubgroups (Fig. 3).
iscussion
n this large, randomized phase III clinical trial in 2,033
atients admitted with AHF and renal dysfunction, treat-
Individual Components of SecondaryEfficacy Endpoint of Persistent WRFTable 2 Individual Components of SecondaryEfficacy Endpoint of Persistent WRF
Placebo Rolofylline
Subjects in ITT population 677 1,356
Subjects with available data for secondary endpoint 644 1,297
Subjects with persistent WRF* 88 (13.7) 195 (15.0)
SCr increase 0.3 mg/dl (days 7 and 14) 72 (81.8) 167 (85.6)
Initiation of hemofiltration or dialysis to day 7 6 (6.8) 6 (3.1)
Death by day 7 14 (15.9) 23 (11.8)
Values are n or n (%). *Numbers of the individual components may add to more than the total n
because it is possible for a patient to be counted in more than 1 component (e.g., SCr increase at
days 7 and 14 and initiation of dialysis by day 7).
ITT  intention to treat; SCr  serum creatinine; WRF  worsening renal function.ent with the adenosine A1 receptor antagonist rolofylline rhad a similar effect as placebo on changes in serum creati-
nine and BUN over 14 days and did not prevent the
development of persistent WRF. However, weight loss was
slightly, but significantly greater, and loop diuretic use
tended to be less in rolofylline-treated patients, indicating a
modest diuretic effect.
Patients admitted with AHF and volume overload have a
high prevalence of baseline renal dysfunction and frequently
experience WRF during hospitalization. In previous studies,
the occurrence of WRF ranged from 12% (both an absolute
increase in serum creatinine 0.3 mg/dl and a percent
increase 25%) to 53% (any increase in serum creatinine),
depending on the definition used (2–4,6,19–21). To ex-
clude patients with a transient increase in creatinine, we
pre-defined persistent WRF as an increase in serum creati-
ine 0.3 mg/dl at both days 7 and 14, or initiation of
emofiltration or dialysis or death by day 7. This explains its
ower occurrence of 15%. Persistent WRF was significantly
ssociated with the presence of anemia, with trends toward
ssociations with poorer baseline renal function and diabe-
es. These findings were very similar to those observed in
ther studies (2–4,6,19,20).
There are several potential mechanisms that underlie
RF and could serve as targets for therapy. Two important
auses of WRF in HF are a decrease in renal blood flow and
n increase in central venous pressure (22–26). The most
requently prescribed drugs in the acute setting are loop
iuretics. Loop diuretics increase sodium and water excre-
ion, and exert venodilator effects, thereby reducing central
enous pressure. However, acute elevations in sodium con-
entration in the distal tubule result in local production of
denosine, which in turn feeds back on the macula densa
nd proximal tubule to cause tubuloglomerular feedback and
ncreased sodium reabsorption, respectively. Stimulation of
enal adenosine A1 receptors located in the afferent arteriole
results in vasoconstriction (27,28). This will lead to a further
decrease in renal blood flow, a decrease in intraglomerular
pressure, and further deterioration of GFR. Therefore,
selective adenosine A1 receptor antagonists have been de-
eloped to treat and/or prevent renal dysfunction associated
ith heart failure.
In 63 patients with stable chronic HF and signs of edema
espite loop diuretics, the adenosine A1 antagonist BG9717
iven as an IV loading dose and infusion increased both
rine output and GFR (11). In contrast, the orally active
denosine A1 antagonist BG9928 did not increase urine
utput or improve creatinine clearance in 50 ambulatory HF
atients, although it did increase natriuresis (29). Studies
ith IV rolofylline in both acute and chronic HF consis-
ently showed an increase in urine output and estimated
FR/creatinine clearance (14–16). In a phase IIb dose-
anging study in 301 patients with AHF and an eCrCl
etween 20 and 80 ml/min (PROTECT Pilot), rolofylline
0 mg/day was associated with improvements in weight,
yspnea, and creatinine clearance, as well as a 50%
eduction in the risk of persistent WRF (16). Based on the
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Renal Effects of Rolofylline in Acute HF May 10, 2011:1899–907results of the PROTECT Pilot study, the 30-mg dose of
rolofylline was chosen for the pivotal phase III PROTECT
study, the design of which was nearly identical to that of the
PROTECT Pilot study (18). Given the consistent findings in
previous studies of adenosine A1 receptor antagonists, includ-
ng the PROTECT Pilot, the current findings were therefore
nexpected. Although more weight loss occurred with rolofyl-
ine than with placebo, suggesting that rolofylline had an
dditional diuretic effect, no improvement in renal function or
Baseline Characteristics According to the Presence or Absence ofTable 3 Baseline Characteristics According to the Presence or
Persistent WRF (n 
Demographics
Age, yrs 72.7 10.2
Male 65.0
Caucasian 95.0
Measurements
Weight, kg 83.2 19.4
Height, cm 168.7 9.0
Systolic BP, mm Hg 125.5 17.9
Diastolic BP, mm Hg 73.6 11.8
Heart rate, beats/min 79.9 15.2
Respiratory rate, breaths/min 20.9 4.5
BNP, pg/ml n  80, 1,280 (883–2
NT-proBNP, pg/ml n  204, 3,000 (3,000–
eCrCl, ml/min 46.0 17.1
LVEF within 6 months, % n  142, 34.2 13
Hgb, g/dl 12.2 1.9
Hgb, g/dl 13 men, 12 women 60.6
Total diuretic dose (IV  oral) on day 1, mg 100 (60–180)
Total diuretic dose (IV  oral) on day 1, mg
40 55 (19.4)
40 to 80 72 (25.4)
80 to 120 45 (15.9)
120 to 160 31 (11.0)
160 80 (28.3)
JVP 10 cm 42.1
Medical history
Heart failure 1 month before admission 94.3
Ischemic heart disease 74.8
Myocardial infarction 51.6
Hypertension 83.0
Atrial fibrillation 52.7
Implantable cardioverter-defibrillator 13.8
Biventricular pacemaker 9.5
Diabetes 43.1
COPD or asthma 24.8
Medical therapy before admission
ACE inhibitor or ARB 71.0
Beta-blocker 72.1
Aldosterone blocker 41.3
Nitrates (oral or topical) 30.0
Digoxin 19.4
Values are mean  SD, %, median (interquartile range), or n (%) unless otherwise indicated. *Diffe
display Hodges-Lehmann nonparametric estimate of between-group difference. Difference in perc
BNP  B-type natriuretic peptide; CI  confidence interval; Hgb  hemoglobin; IV  intraveno
eptide; other abbreviations as in Tables 1 and 2.revention of persistent WRF was observed. iSeveral potential explanations can be offered for the
ifference between the previous smaller studies and the
resent large study, of which many can be rejected. First, a
ifference in patient characteristics is unlikely to explain
hese findings as the patient population of the PROTECT
ilot study was almost identical to the current PROTECT
rial (17). This was expected, because similar enrollment
riteria were used. However, subgroup analysis showed a
rend toward a more pronounced effect on clinical outcomes
istent WRFnce of Persistent WRF
No Persistent WRF (n  1,658) Difference (95% CI)*
69.7 11.8 3.0 (1.5 to 4.4)
67.2 2.2 (8.2 to 3.8)
95.6 0.6 (3.3 to 2.2)
81.8 19.5 1.4 (1.1 to 3.8)
168.5 9.2 0.3 (0.9 to 1.4)
124.2 17.5 1.4 (0.9 to 3.6)
73.9 11.8 0.3 (1.8 to 1.1)
80.3 15.5 0.4 (2.3 to 1.6)
21.3 4.5 0.4 (1.0 to 0.2)
n  429, 1,260 (825–2,259) 11 (163 to 185)
n  1,252, 3,000 (3,000–3,730) NA
51.4 20.5 5.4 (7.9 to2.8)
n  788, 31.9 12.8 2.3 (0.0 to 4.6)
12.8 2.0 0.6 (0.9 to0.4)
47.3 13.3 (6.8 to 19.8)
100 (60–165) 0 (0 to 13)
302 (18.2)
460 (27.7)
321 (19.4)
157 (9.5)
418 (25.2)
40.7 1.4 (5.2 to 7.9)
95.0 0.6 (3.5 to 2.2)
68.7 6.2 (0.6 to 11.7)
49.3 2.3 (4.0 to 8.6)
78.8 4.2 (0.6 to 9.0)
54.9 2.2 (8.5 to 4.1)
16.1 2.3 (6.7 to 2.1)
9.9 0.4 (4.1 to 3.4)
45.8 2.7 (8.9 to 3.6)
19.2 5.7 (0.3 to 11.1)
76.5 5.5 (11.1 to 0.2)
77.3 5.2 (10.8 to 0.4)
44.8 3.5 (9.7 to 2.7)
25.0 5.0 (0.7 to 10.7)
30.1 10.7 (15.8 to5.6)
n means for continuous variables, except for BNP, NT-proBNP, and total diuretic dose, all of which
s for binary variables.
 jugular venous pressure; NA  not applicable; NT-proBNP  N-terminal pro–B-type natriureticPersAbse
283)
,125)
4,696)
.9
rence i
entage
us; JVPn patients with more severe renal impairment at baseline,
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pronounced in patients with greater renal dysfunction.
These findings should, however, be interpreted with caution
because they represent 1 of many subgroup analyses per-
formed without adjustment for multiplicity for an endpoint
Figure 2 Primary Endpoint in Relation to Baseline Renal Functi
Primary endpoint of treatment success, unchanged, or failure in placebo and rolof
CI  confidence interval; OR  odds ratio.
Univariable and Multivariable Predictors of Persistent WRFTable 4 Univariable and Multivariable Predictors of Persistent
Variable OR per Unit for Continuous Variab
Age, yrs 10 yrs
Male
Hypertension
Baseline CrCl, ml/min 10 ml/min
Diabetes
Hemoglobin (13 men, 12 women)
Total diuretic dose (IV  oral) on day 1, mg
JVP (10 cm)
Ischemic heart disease
Rolofylline Rx
*Odds ratios [ORs], 95% CIs, and p values from logistic regression models.
CrCl  creatinine clearance; Rx  treatment; other abbreviations as in Tables 2 and 3.in which the overall treatment effect was not statistically
significant.
In contrast to the study by Givertz et al. (15), which
suggested a diuretic-sparing effect of rolofylline, the cumu-
lative dose of IV loop diuretics was similar in both the
reated patients according to baseline estimated creatinine clearance (eCrCl).
Univariable OR (95% CI), p Value* Multivariable OR (95% CI), p Value*
1.27 (1.13–1.42), p  0.001 1.14 (0.99–1.31), p  0.070
0.91 (0.70–1.18), p  0.473 0.95 (0.72–1.26), p  0.715
1.32 (0.94–1.83), p  0.106 1.22 (0.86–1.74), p  0.272
0.86 (0.81–0.93), p  0.001 0.92 (0.85–1.00), p  0.061
0.90 (0.70–1.16), p  0.400 0.77 (0.58–1.01), p  0.058
1.72 (1.31–2.25), p  0.001 1.60 (1.20–2.14), p  0.001
1.04 (0.95–1.13), p  0.427 1.03 (0.94–1.13), p  0.553
1.06 (0.81–1.39), p  0.679 1.09 (0.83–1.45), p  0.533
1.36 (1.02–1.81), p  0.038 1.27 (0.94–1.73), p  0.120
1.12 (0.85–1.47), p  0.421 1.10 (0.83–1.45), p  0.514on
ylline tWRF
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Renal Effects of Rolofylline in Acute HF May 10, 2011:1899–907placebo and rolofylline groups. The finding that weight loss
was more pronounced in the rolofylline group despite
similar doses of diuretics indicates greater diuresis with the
combination of rolofylline and loop diuretics than with loop
diuretics alone. This enhanced diuretic effect might have
offset the effects of rolofylline on preservation of renal
function, which might be an explanation for the observed
absence of renoprotective effects of adenosine A1 blockade
n the present study. In prior studies by Gottlieb et al. (11)
nd Dittrich et al. (14) in chronic HF outpatients treated
ith identical doses of furosemide, addition of an adenosine
1 antagonist improved both diuresis and renal function
ompared with use of placebo. However, these patients were
linically stable and were not required to be volume-
verloaded. Because PROTECT is the largest study to
ate of the effects of an adenosine A1 antagonist on renal
unction, the beneficial effects seen in prior studies might
e related to chance findings due to small sample size.
he proof-of-concept studies by Givertz et al. (15) were
ot powered to assess the effects of rolofylline on renal
Figure 3 Risk of Morbidity and Mortality in Relation to Baselin
Kaplan-Meier plot showing rates of death or cardiovascular or renal rehospitalization throu
HR  hazard ratio; other abbreviations as in Figure 2.unction in AHF, and in patients with chronic HFtudied by Greenberg et al. (29), no effects of BG9928
ere observed on either urine volume or renal function.
reliminary data from the TRIDENT-1 (Phase 2b Study
o Assess the Safety and Tolerability of IV Tonapofylline
n Subjects With Acute Decompensated Heart Failure
nd Renal Insufficiency) study also shows no benefit of IV
G9928 (tonopofylline) on renal function in AHF (30).
The definition of persistent WRF used in PROTECT is
distinct from most studies of WRF in which an increase
in serum creatinine of 0.3 mg/dl at any time during the
hospitalization was considered clinically significant. The
current, more conservative definition was similar to that
used in the PROTECT Pilot study and was specifically
designed to exclude patients with transient WRF. The
relatively low incidence of persistent WRF that we
observed is noteworthy and may be due to changes in
AHF management that have occurred since the recogni-
tion of WRF as an emerging problem with prognostic
implications. Use of lower doses of loop diuretics or
renin-angiotensin system inhibitors, more careful atten-
al Function
60 in placebo- and rolofylline-treated patients according to baseline eCrCl.e Ren
gh daytion to blood pressure or daily changes in renal function,
11
1
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May 10, 2011:1899–907 Renal Effects of Rolofylline in Acute HFor changes in hospital length of stay could explain this
observation.
Conclusions
In this large phase III study, rolofylline exerted modest diuretic
effects, but had no protective effect on renal function in AHF
patients with mild to moderate renal dysfunction.
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